The importance of glucocorticoid receptors in systemic lupus erythaematosus. A systematic review

Autoimmunity Reviews

Volumn 14, Issue 4, 2015, Pages 349-351

  Bazsó, Anna ^a   Szappanos, Ágnes ^a   Patócs, Attila ^b   Poór, Gyula ^a,b   Shoenfeld, Yehuda ^c   Kiss, Emese ^a,b  

^a NATIONAL INSTITUTE OF RHEUMATOLOGY AND PHYSIOTHERAPY   (Hungary)

^b SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

Genetic polymorphisms; Glucocorticoid receptors; Glucocorticoids; SLE

Indexed keywords

GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; ANTIINFLAMMATORY AGENT;

ANTIINFLAMMATORY ACTIVITY; AUTOCRINE EFFECT; CELL PROLIFERATION; DISEASE ACTIVITY; DRUG EFFICACY; GENE CONTROL; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HUMAN; HYPOPHYSIS ADRENAL SYSTEM; IMMUNOSUPPRESSIVE TREATMENT; PARACRINE SIGNALING; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMATIC REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; LUPUS ERYTHEMATOSUS, SYSTEMIC; METABOLISM;

ANTI-INFLAMMATORY AGENTS; GLUCOCORTICOIDS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; RECEPTORS, GLUCOCORTICOID; SIGNAL TRANSDUCTION;

EID: 84923075709     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2014.12.007     Document Type: Review

References (39)

1. Hochberg M.C. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997, 40(9):1725.
2. Borchers A.T., Naguwa S.M., Shoenfeld Y., Gershwin M.E. The geoepidemiology of systemic lupus erythematosus. Autoimmun Rev 2010, 9(5):A277-A287.
3. Gurevitz S.L., Snyder J.A., Wessel E.K., Frey J, Williamson BA, et al. Systemic lupus erythematosus: a review of the disease and treatment options. Consult Pharm 2013, 28(2):110-121.
4. Mosca M., Tani C., Carli L., Bombardieri S. Glucocorticoids in systemic lupus erythematosus. Clin Exp Rheumatol Sep-Oct 2011, 29(5 Suppl. 68):S126-S129.
5. Seguro L.P., Rosario C., Shoenfeld Y. Long-term complication of past glucocorticoid us. Autoimmun Rev 2013, 12(5):629-632.
6. Arnaud L., Zahr N., Costedoat-Chalumeau N., Amoura Z, et al. The importance of assessing medication exposure to the definition of refractory disease insystemic lupus erythematosus. Autoimmun Rev 2011, 10(11):674-678.
7. Gladman D.D., Urowitz M.B., Doris F., Lewandowski K., Anhorn K, et al. Glucocorticoid receptors in systemic lupus erythematosus. J Rheumatol 1991, 18:681-684.
8. Lu N.Z., Cidlowski J.A. The origin and functions of multiple human glucocorticoid receptor isoforms. Ann N Y Acad Sci 2004, 1024:102-123.
9. Cutolo M., Capellino S., Sulli A., Serioli B, Secchi ME, Villaggio B, et al. Estrogens and autoimmune diseases. Ann N Y Acad Sci 2006, 1089:538-547.
10. Czock D., Keller F., Rasche F.M., Haussler U, et al. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet 2005, 44(1):61-98.
11. Turnbull A.V., Rivier C.L. Regulation of the hypothalamic-pituitary-adrenal axis by cytokines: actions and mechanisms of action. Physiol Rev 1999, 79(1):1-71.
12. Besedovsky H.O., del Rey A. The cytokine-HPA axis feed-back circuit. Z Rheumatol 2000, 59:26-30.
13. Hardy R.S., Raza K., Cooper M.S. Endogenous glucocorticoids in inflammation: contributions of systemic and local responses. Swiss Med Wkly 2012, 42:w13650.
14. Schaaf M.J., Cidlowski J.A. Molecular mechanisms of glucocorticoid action and resistance. J Steroid Biochem Mol Biol 2002, 83(1-5):37-48.
15. Tomlinson J.W., Walker E.A., Bujalska I.J., Draper N., Lavery G.G., Cooper M.S., et al. 11beta-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoidresponse. Endocr Rev 2004, 25(5):831-866.
16. Besedovsky H.O., del Rey A. Regulating inflammation by glucocorticoids. Nat Immunol 2006, 7(6):537.
17. Encio I.J., Detera-Wadleigh S.D. The genomic structure of the human glucocorticoid receptor. J Biol Chem 1991, 266(11):7182-7188.
18. Pelaia G., Vatrella A., Cuda G., Maselli R., Marsico S.A. Molecular mechanisms of corticosteroid actions in chronic inflammatory airway diseases. Life Sci 2003, 72(14):1549-1561.
19. Davies T.H., Ning Y.M., Sánchez E.R. Differential control of glucocorticoid receptor hormone-binding function by tetratricopeptide repeat (TPR) proteins and the immunosuppressive ligand FK506. Biochemistry 2005, 44(6):2030-2038.
20. Tian S., Poukka H., Palvimo J.J., Janne O.A. Small ubiquitin-related modifier-1 (SUMO-1) modification of the glucocorticoid receptor. Biochem J 2002, 367(Pt 3):907-911.
21. Schoneveld O.J., Gaemers I.C., Lamers W.H. Mechanisms of glucocorticoid signalling. Biochim Biophys Acta 2004, 1680(2):114-128.
22. Bladh L.G., Lidén J., Pazirandeh A., Rafter I., Dahlman-Wright K., Nilsson S., et al. Identification of target genes involved in the antiproliferative effect of glucocorticoids reveals a role for nuclear factor-(kappa)B repression. Mol Endocrinol 2005, 19(3):632-643.
23. Cavalcante L.O., Melo M.R., Dinis V.G., Castro R.B., Souza B.D., Longui C.A. Quantitation of glucocorticoid receptor alpha and NF-κB pathway mRNA and its correlation with disease activity in rheumatoid arthritis patients. Genet Mol Res 2010, 9(4):2300-2310.
24. Cascallana J.L., Bravo A., Donet E., Leis H., Lara M.F., Paramio JM, et al. Ectoderm-targeted overexpression of the glucocorticoid receptor induces hypohidrotic ectodermal dysplasia. Endocrinology 2005, 146(6):2629-2638.
25. Ma Y., Ryu J.S., Dulay A., Segal M., Guller S. Regulation of plasminogen activator inhibitor (PAI)-1 expression in a human trophoblast cell line by glucocorticoid (GC) and transforming growth factor (TGF)-beta. Placenta 2002, 23(10):727-734.
26. Bruna A., Nicolàs M., Muñoz A., Kyriakis J.M., Caelles C. Glucocorticoid receptor-JNK interaction mediates inhibition of the JNK pathway by glucocorticoids. EMBO J. 2003, 22(22):6035-6044.
27. Flammer J.R., Rogatsky I. Minireview: glucocorticoids in autoimmunity: unexpected targets and mechanisms. Mol Endocrinol 2011, 25(7):1075-1086.
28. Auphan N., DiDonato J.A., Rosette C., Helmberg A., Karin M. Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 1995, 270(5234):286-290.
29. Lannan E.A., Galliher-Beckley A.J., Scoltock A.B., Scoltock A.B., Cidlowski J.A. Proinflammatory actions of glucocorticoids: glucocorticoids and TNFα coregulate gene expression in vitro and in vivo. Endocrinology 2012, 153(8):3701-3712.
30. Ibañez D., Urowitz M.B., Gladman D.D. Summarizing disease features over time: I. Adjusted mean SLEDAI derivation and application to an index of disease activity in lupus. J Rheumatol 2003, 30(9):1977-1982.
31. Spies C.M., Bijlsma J.W., Burmester G.R., Buttgereit F. Pharmacology of glucocorticoids in rheumatoid arthritis. Curr Opin Pharmacol 2010, 10(3):302-307.
32. van Everdingen A.A., Huisman A.M., Wenting M.J., van Reesema S., Jacobs J.W., Bijlsma J.W. Down regulation of glucocorticoid receptors in early-diagnosed rheumatoid arthritis. Clin Exp Rheumatol 2002, 20(4):463-468.
33. Samson M., Puéchal X., Devilliers H., Ribi C., Cohen P., Bienvenu B., et al. Long-term follow-up of a randomized trial on 118 patients with polyarteritis nodosa or microscopic polyangiitis without poor-prognosis factors. Autoimmun Rev 2014, 13(2):197-205.
34. Holle J.U., Gross W.L. Treatment of ANCA-associated vasculitides (AAV). Autoimmun Rev 2013, 12(4):483-486.
35. Tanaka H., Akama H., Ichikawa Y., Makino I., Homma M. Glucocorticoid receptor in patients with lupus nephritis: relationship between receptor levels in mononuclear leukocytes and effect of glucocorticoid therapy. J Rheumatol 1992, 19(6):878-883.
36. Li X., Zhang F.S., Zhang J.H., Wang J.Y. Negative relationship between expression of glucocorticoid receptor alpha and disease activity: glucocorticoid treatment of patients with systemic lupus erythematosus. J Rheumatol 2010, 37(2):316-321.
37. Zou Y.F., Xu J.H., Wang F., Liu S., Tao J.H., Cai J., et al. Association study of glucocorticoid receptor genetic polymorphisms with efficacy of glucocorticoids in systemiclupus erythematosus: a prospective cohort study. Autoimmunity 2013, 46(8):531-536.
38. Quax R.A., Peeters R.P., Feelders R.A. Selective glucocorticoid receptor modulators: future of glucocorticoid immunosuppressive therapy?. Endocrinology 2011, 152(8):2927-2929.
39. Luijten R.K., Fritsch-Stork R.D., Bijlsma J.W., Derksen R.H., et al. The use of glucocorticoids in systemic lupus erythematosus. After 60 years still more an art than science. Autoimmun Rev 2013, 12(5):617-628.